

Wednesday, October 20, 2010 2010 ACCP Annual Meeting Austin, TX

ORIGINAL RESEARCH

ADR/Drug Interactions

1. A Phase 1, Single-Center, Open-Label, Randomized, Two-Period Cross-Over Study, to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Sanctura XR and Glucophage.
Michael G. Oefelein, M.D., FACS,¹ Warren Tong, Pharm.D.,¹ Sam Kerr, Pharm.D.,¹ Kavitha Bhasi, Pharm.D.,¹ Rina Patel, M.S.,¹ Dale Yu, Ph.D.²; (1)Allergan, LLC, Irvine, CA; (2)Clinical Pharmacology Department, Allergan, Irvine, CA
2. Clopidogrel and Proton Pump Inhibitor Co-prescribing (CLAP COP) Study.
Charles F. Seifert, Pharm.D.; Texas Tech University Health Sciences Center School of Pharmacy, Lubbock, TX

Adult Medicine

3. The Incidence of Hypoglycemia: A Comparison of Two Insulin Protocols in a Community Hospital.
Krisan Anderson, Pharm.D.,¹ Amy R. Donaldson, Pharm.D., BCPS,² Cara L. Léos, Pharm.D., BCPS,³ Christine C Ricci, Pharm.D., BCPS⁴; (1)East Alabama Medical Center and Auburn University Harrison School of Pharmacy, Opelika, AL; (2)Auburn University Harrison School of Pharmacy, Auburn, AL; (3)Auburn University Harrison School of Pharmacy, Auburn University, AL; (4)East Alabama Medical Center, Opelika, AL
4. Evaluation of Pneumococcal Vaccination Rates After Vaccine Protocol Changes.
Jennifer G. Smith, Pharm.D.,¹ Nicole L. Metzger, Pharm.D.²; (1)Emory Healthcare, Atlanta, GA; (2)Mercer University College of Pharmacy and Health Sciences, Atlanta, GA
- 5E. Risk of Hypoglycemia in Hospitalized Patients Prescribed a Sulfonylurea.
Christina M. Hedrick, Pharm.D.,¹ Amy C. Donihi, Pharm.D., BCPS,² Kim Coley, Pharm.D.²; (1)University of Pittsburgh Medical Center Presbyterian, Pittsburgh, PA; (2)University of Pittsburgh School of Pharmacy, Pittsburgh, PA
6. An Assessment of the Compliance with Standards of Care for Erythropoiesis-Stimulating Agents.
Tara E. Gleason, Pharm.D., Julie A. Murphy, Pharm.D., BCPS; St. Louis College of Pharmacy, St. Louis, MO

Allergy

7E. Bepreve™ 1.5% Reduces Rhinorrhea for at Least 16 Hours: An Integrated Analysis of Two Phase 3 Conjunctival Allergen Challenge (CAC) Clinical Trials.
Timothy R. McNamara, Pharm.D.,¹ Jon I. Williams, Ph.D.,¹ James A. Gow, M.D.,¹ Paul J. Gomes, M.D.,² Mark B. Abelson, M.D.³; (1)ISTA Pharmaceuticals, Inc., Irvine, CA; (2)ORA Clinical Research & Development, Inc., Andover, MA; (3)Harvard Medical School, Boston, MA

Clinical Research Study Design

42. A Rigorous Methodology for Small Sample Clinical Pharmacy Research: Evaluation of Insulin Dosing Strategies in Four Nursing Home Patients with Diabetes.
Deanne L. Hall, Pharm.D., CDE,¹ Thomas Pineo, D.O.,² Ty Ridenour, Ph.D.³; (1)University of Pittsburgh School of Pharmacy/University of Pittsburgh Medical Center, Pittsburgh, PA; (2)UPMC Horizon, Community Medicine Incorporated, Greenville Medical Center, Family Medicine, Greenville, PA; (3)University of Pittsburgh School of Pharmacy, Pittsburgh, PA

Community Pharmacy Practice

43E. Association Between Exposure to Diabetes Self-Management Education and Disease State Knowledge and Hemoglobin A1c Levels.
Jonathan Newsome, Pharm.D.,¹ Janel Bailey-Wheeler, Pharm.D.,² Daniel Sarpong, Ph.D.³; (1)Hampton University, Newport News, VA; (2)Xavier University of Louisiana, New Orleans, LA; (3)Jackson State University, Jackson, MS

44. Medicare Part D in Community Pharmacy: Continued Impact and Related Issues.
Shamima Khan, MBA, Ph.D., Carmela Avena-Woods, RPh, Pharm.D., CGP; St. John's University, Jamaica, NY

Critical Care

45E. Does Withholding Early Intravenous Fat Emulsions from Parenteral Nutrition Reduce Infections During Critical Illness?
Anthony Gerlach, Pharm.D., BCPS,¹ Sheela Thomas, M.S., RD,¹ Claire V. Murphy, Pharm.D., BCPS,¹ Lydia Pourzanjani, M.S., RD, LD,² Melissa Whitmill, M.D.,¹ Steven Steinberg, M.D.,¹ Stanislaw Stawicki, M.D.,¹ Charles H. Cook, M.D.¹; (1)The Ohio State University Medical Center, Columbus, OH; (2)The Ohio State University Medical Center, Columbus, OH

46. Evaluation of Corticosteroid Use in Septic Shock (ECUSS): A Retrospective Multicenter Study.
Marc M. Perreault, Pharm.D., BCPS,¹ Patrick Bouchard, MSc,¹ Zoe Thiboutot, MSc,¹ David R. Williamson, MScPharm, BCPS,² Salmaan Kanji, Pharm.D.,³ Lisa D.

Burry, BSPHarm, Pharm.D., FCCP⁴; (1)The Montreal General Hospital, Montreal, QC, Canada; (2)Faculté de Pharmacie, Université de Montréal, Montreal, QC, Canada; (3)The Ottawa Hospital, Ottawa, ON, Canada; (4)Mount Sinai Hospital, Toronto, ON, Canada

47. A Retrospective Analysis of Mortality and Patient Outcomes in Trauma Patients Admitted to the ICU with Elevated INR Values.

Brenna A. Ferry, Pharm.D., Lee E. Morrow, M.D., FCCP, Samuel Cemaj, M.D., Tammy L. Burns, Pharm.D., BCPS, Megan B. Sorensen, RN, MHA, Mark A. Malesker, Pharm.D., FCCP, BCPS; Creighton University Medical Center, Omaha, NE

48. A Retrospective Analysis of Quetiapine Use in the Intensive Care Unit.

Cara M. Olsen, Pharm.D., Lee E. Morrow, M.D., FCCP, Mark A. Malesker, Pharm.D., FCCP, BCPS; Creighton University Medical Center, Omaha, NE

49. Economic Evaluation of a Point-of-Care Blood Glucose Value.

Mark A. Malesker, Pharm.D., FCCP, BCPS, Daniel E. Hilleman, Pharm.D., FCCP, Lee E. Morrow, M.D., FCCP; Creighton University Medical Center, Omaha, NE

50. Noncompliance with ATS-IDSA Guidelines' Empiric Antibiotic Therapy for Pneumonia.

Kyle W. Bierman, Pharm.D., Lee E. Morrow, M.D., Josh D. Holweger, M.D., John Ratelle, M.D., Mark A. Malesker, Pharm.D., FCCP, BCPS; Creighton University Medical Center, Omaha, NE

51. Is Healthcare-Associated Pneumonia More Similar to Community-Acquired Pneumonia than We Think?

Kyle W. Bierman, Pharm.D., Lee E. Morrow, M.D., FCCP, Josh D. Holweger, M.D., John Ratelle, M.D., Mark A. Malesker, Pharm.D., FCCP, BCPS; Creighton University Medical Center, Omaha, NE

52. Is Healthcare-Associated Pneumonia a Good Predictor of Infection with Antibiotic-Resistant Pathogens?

Kyle W. Bierman, Pharm.D., Lee E. Morrow, M.D., FCCP, Josh D. Holweger, M.D., John Ratelle, M.D., Mark A. Malesker, Pharm.D., FCCP, BCPS; Creighton University Medical Center, Omaha, NE

53E. Effect of a Silver-Coated Endotracheal Tube on Ventilator-Associated Pneumonia and Medical Resource Utilization in Clinical Practice.

Lee E. Morrow, M.D., FCCP, Edward Mintz, M.D., Mark A. Malesker, Pharm.D., FCCP, BCPS; Creighton University Medical Center, Omaha, NE

54. Adequacy of International Normalized Ratio (INR) Reversal After Receiving 3-Factor Prothrombin Complex Concentrate.

Jennifer H. Baggs, Pharm.D., Asad E. Patanwala, Pharm.D., Evan Williams, Pharm.D., Candidate, Brian L. Erstad, Pharm.D.; University of Arizona, Tucson, AZ

55. The Impact of a Registered Nurse-Driven Electrolyte Replacement Protocol in the Intensive Care Unit.

Linda A. Sitkiewicz, Pharm.D., Meera Patel, Pharm.D., Daniel Feinstein, M.D.; Moses H. Cone Memorial Hospital, Greensboro, NC

56. Hydrocortisone Plus Fludrocortisone versus Hydrocortisone Alone for Vasopressor-Dependent Septic Shock.

Jessica L. Brown, Pharm.D., Nita Johnston, Pharm.D., Meera Patel, Pharm.D., Daniel Feinstein, M.D.; Moses Cone Health System, Greensboro, NC

57E. Effect of Organ Dysfunction on Sedative and Analgesic Prescribing and Dosing in Mechanically Ventilated ICU Patients.

Stacy A. Voils, Pharm.D.,¹ *Gregory Chenault, Pharm.D.*,² *Kimberly Varney, Pharm.D.*,³ *Gretchen M. Brophy, Pharm.D.*⁴; (1)Virginia Commonwealth University Health System, Richmond, VA; (2)Virginia Commonwealth University Medical Center, Richmond, VA; (3)VCU Medical Center, Richmond, VA; (4)VCU Medical College of Virginia, Richmond, VA

58. Effect of Real-time Unit-Level Visualization of Prophylaxis Status on the Incidence of Venous Thromboembolism in a Surgical Intensive Care Unit.

Melissa M. Chesson, Pharm.D., Alley Killian, Pharm.D., Candace Stearns, Pharm.D., Jason Stein, M.D.; Emory Healthcare, Atlanta, GA

Drug Information

59E. Investigation of Blood-Brain Barrier (BBB) Permeability and Immune-Cell Population of Brain Tissue in Belatacept-Treated Monkeys.

W.J. Freebern, M.D.; Drug Safety Evaluation, Research and Development, Bristol-Myers Squibb, Syracuse, NY

60. Midwest Residents' Understanding of Basic Concepts of Evidence-Based Medicine and Perception of Drug Information Preparation Before and After Residency Training.

Amy F. Wilson, Pharm.D., Philip J. Gregory, Pharm.D., Zara Risoldi Cochrane, Pharm.D.; Center for Drug Information and Evidence-Based Practice (CDIEBP), Creighton University School of Pharmacy and Health Professions, Omaha, NE

Emergency Medicine

85. Do Elderly Patients Require Less Propofol for Procedural Sedation in the Emergency Department?

Anna C. Christich, Pharm.D., Karalea D. Jasiak, Pharm.D., Christopher J. Edwards, Pharm.D., Hanna Phan, Pharm.D., Asad E. Patanwala, Pharm.D.; University of Arizona, Tucson, AZ

86E. The Effect of a Medical Resident Educational Program on Emergency Department Pharmacy Interventions and Medication Errors.

Megan E. Foster, Pharm.D.,¹ Randy Bradley, Ph.D.,² Donald E. Lighter, M.D., MBA,³ Brandon Edgeron, Pharm.D.,¹ Sandip A. Godambe, M.D., Ph.D., MBA⁴; (1)Le Bonheur Children's Medical Center, Department of Pharmacy, Memphis, TN; (2)Business Administration, University of Tennessee-Knoxville, Knoxville, TN; (3)Business Administration, University of Tennessee-Knoxville, and Institute of Health Care Quality, Knoxville, TN; (4)Pediatric Emergency Medicine, University of Tennessee Health Science Center, Memphis, TN

87. Validation of a Risk Quantification Instrument for Acute Acetaminophen Overdose Patients Treated with N-acetylcysteine at a University Teaching Hospital.

Kyle A. Weant, Pharm.D., BCPS, A. Kendall Gross, Pharm.D., Stephanie N. Baker, Pharm.D.; University of Kentucky HealthCare, Department of Pharmacy Services, Lexington, KY

88. Results of a Multidisciplinary Survey Evaluating a Pediatric Emergency Department's Satisfaction with Implementation of ED-Based Pharmacy Services: A Two-Year Review.

Megan E. Foster, Pharm.D.,¹ Brandon Edgeron, Pharm.D.,¹ Sandip A. Godambe, M.D., Ph.D., MBA²; (1)Le Bonheur Children's Medical Center, Department of Pharmacy, Memphis, TN; (2)Pediatric Emergency Medicine, University of Tennessee Health Science Center, Memphis, TN

89. Retrospective Review of the Treatment of Hypertensive Emergency in an Academic Medical Center Emergency Department.

Lindsey M. Clark, Pharm.D., Nicole Harger, Pharm.D., BCPS, Michelle Wiest, Pharm.D., BCPS; University Hospital, Cincinnati, OH

Geriatrics

94. Cross-sectional Study of Gabapentin for Sleep.

Lisa C. Hutchison, Pharm.D., MPH, Catherine E. O'Brien, Pharm.D.; University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR

95. Gastrointestinal Tolerability of NSAIDs in Elderly Arthritis Patients.

Margaret Noyes Essex, Pharm.D., Sharon R. Mallen, M.D., Richard Y. Zhang, Ph.D.; Pfizer Medical, New York, NY

96. Results of an Independent Pharmacist-Managed Oral Anticoagulation Service in a Long-term Care Facility.

Haley M. Phillippe, Pharm.D.; Harrison School of Pharmacy, Owens Cross Roads, AL

97. Evaluation of the Role of Clinical Pharmacists in Nitrofurantoin Stewardship at a Long-term Care Facility.

Amber N. McLendon, Pharm.D., C. Brock Woodis, Pharm.D.; Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC

98E. Anticholinergic Burden of Older Adults in the Community.

Teri L. West, Pharm.D., Maria C. Pruchnicki, Pharm.D., Ruth E. Emptage, Pharm.D.; The Ohio State University, Columbus, OH

Health Services Research

99. A Multicenter, Retrospective Chart Review Study Comparing Therapy Change Rates in Open-Angle Glaucoma or Ocular Hypertension Patients Newly Treated with Latanoprost (LAT) or Travoprost-Z (TRAV-Z) Monotherapy.

J. Fain, Ph.D., RPh,¹ S. Kotak, BSP Pharm, M.S.,¹ J. Mardekian, Ph.D.,¹ J. Bacharach, M.D.,² D. Edward, M.D.,³ S. Rauchman, M.D.,⁴ T. Brevetti, M.D.,¹ J. Fox, Pharm.D.,¹ C. Lovelace, Pharm.D., JD¹; (1)Pfizer Ophthalmics, New York, NY; (2)North Bay Eye Associates, Petaluma, CA; (3)Summa Health System, Akron, OH; (4)North Valley Eye, Mission Hills, CA

100. The Impact of a Pharmacist on a Short-term Medical Mission Trip.

Jennifer N. Clements, Pharm.D., Michelle Horn, Pharm.D., Emily Vescovi, Pharm.D.; Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA

101. The Effects of Dosing Complexity on Adherence with Prescription Medications Commonly Used for Cardiovascular Patients.

Jay P. Bae, Ph.D.,¹ Paul P. Dobesh, Pharm.D.,² Johnna D. Anderson, M.S.,¹ Anthony Zagar, M.S.,¹ Donald G. Klepser, Ph.D., MBA,² Patrick L. McCollam, Pharm.D.,¹ Molly E. Tomlin, M.S.¹; (1)Eli Lilly & Company, Indianapolis, IN; (2)University of Nebraska Medical Center, Omaha, NE

102. An Evaluation of Once- versus Twice-Daily Dosing on Persistence with Prescription Medications in Cardiovascular Patients.

Jay P. Bae, Ph.D.,¹ Paul P. Dobesh, Pharm.D.,² Anthony Zagar, M.S.,¹ Johnna D. Anderson, M.S.,¹ Molly E. Tomlin, M.S.,¹ Patrick L. McCollam, Pharm.D.,¹ Donald G. Klepser, Ph.D., MBA²; (1)Eli Lilly & Company, Indianapolis, IN; (2)University of Nebraska Medical Center, Omaha, NE

Medication Safety

158. Differences in Complexity of Medication Regimens for Males and Females Discharged from Acute Care Following Joint Arthroplasty.

Megan Willson, Pharm.D.,¹ Douglas L. Weeks, Ph.D.,² Chris L. Greer, BPharm³; (1)Washington State University Spokane, Spokane, WA; (2)Washington State University, Inland Northwest Health Services, Spokane, WA; (3)St. Luke's Rehabilitation Institute, Spokane, WA

159. Mechanism of Echinocandin-Induced Cardiotoxicity.

Kayla R. Stover, Pharm.D., BCPS,¹ John D. Cleary, Pharm.D.,² Jerry Farley, Ph.D.,² Glenn A. Hoskins, Researcher,² March D. Ard, Ph.D.²; (1)The University of Mississippi School of Pharmacy, Jackson, MS; (2)University of Mississippi Medical Center, Jackson, MS

160. Identification of the Causes of Medication Errors in Inpatients Infected with Human Immunodeficiency Virus.

Jessica L. Adams, Pharm.D.,¹ Mark T. Sawkin, Pharm.D.,² Rachel Chambers, Pharm.D.,³ Susan L. Davis, Pharm.D.,³ Megan Winegardner, Pharm.D.³; (1)University of North Carolina at Chapel Hill – Eshelman School of Pharmacy, Chapel Hill, NC; (2)University of Missouri–Kansas City, Kansas City Free Health Clinic, Kansas City, MO; (3)Henry Ford Hospital, Detroit, MI

161. Medication Errors During Medical Emergencies in a Large, Tertiary Care, Academic Medical Center.

Roman Gokhman, Pharm.D.,¹ Sandra L. Kane-Gill, Pharm.D., MSc,² Paul Phrampus, M.D.,¹ Amy L. Seybert, Pharm.D.¹; (1)University of Pittsburgh Medical Center, Pittsburgh, PA; (2)University of Pittsburgh, Pittsburgh, PA

162. Evaluation of a Pharmacist-Conducted Medication Reconciliation Program upon Admission in a Medical Center in Taiwan.

Yen-Ying Lee, M.S., Pharm.D., Tzu-Ying Wu, RPh, Mu-Lung Chen, M.S., Jing-Yi Hou, RPh, Hsiang-Yin Chen, M.S., Pharm.D.; Taipei Medical University-Wan Fang Hospital, Taipei, Taiwan

163. FMEA Utilization to Improve Warfarin Use at an Urban Teaching Hospital.

Abir O. Kanaan, Pharm.D.,¹ Kristin Tuiskula, Pharm.D.,¹ Jason T. Andree, Pharm.D.,² Matthew A. Silva, Pharm.D., BCPS,¹ Michael J. Ditoro, Pharm.D.,² V. Susan George, M.D., FACP,¹ George Abraham, M.D., MPH, FACP¹; (1)Massachusetts College of Pharmacy and Health Sciences, Worcester, MA; (2)St. Vincent Hospital, Worcester, MA

164. Successful Design, Implementation, and Quantification of a Community-Based Medication Collection Program.

Laura Perry, Pharm.D.,¹ Bradley W. Shinn, Pharm.D.,² John S. Stanovich, B.S.³; (1)The University of Findlay College of Pharmacy, Findlay, OH; (2)University of Findlay School of Pharmacy, Findlay, OH; (3)University of Findlay, Findlay, OH

165. Failure of Risk Evaluation and Mitigation Strategies with Bosentan.

Lori A. Wilken, Pharm.D., Louis Kim, Pharm.D., Christopher Lee, B.S., JoAnn Stubbings, RPh, MHCA, Juliana Chan, Pharm.D.; University of Illinois at Chicago College of Pharmacy, Chicago, IL

166E. Extrapyramidal Symptom and Akathisia Profile of Iloperidone in Schizophrenia Clinical Trials.

John Lauriello, M.D.,¹ Joy Kainer, RPh, Pharm.D.,² *Marla Hochfeld, M.D.*,² Rosarelis Torres, Ph.D.,³ Curt D. Wolfgang, Ph.D.,³ John Feeney, M.D.³; (1)University of New Mexico, Albuquerque, NM; (2)Novartis Pharmaceuticals Corporation, East Hanover, NJ; (3)Vanda Pharmaceuticals Inc., Rockville, MD

167E. The Metabolic Profile of Iloperidone: Summary of Phase II and III Schizophrenia Trials.

Stephen M. Stahl, M.D., Ph.D.,¹ *Joy Kainer, RPh, Pharm.D.*,² *Marla Hochfeld, M.D.*,² *Paolo Baroldi, M.D., Ph.D.*,³ *John Feeney, M.D.*,³ *Curt D. Wolfgang, Ph.D.*³; (1)University of California, San Diego, La Jolla, CA; (2)Novartis Pharmaceuticals Corporation, East Hanover, NJ; (3)Vanda Pharmaceuticals Inc., Rockville, MD

168. Use of a Computerized On-screen Alert to Reduce Weight-Entry Errors in an Electronic Medical Record at a Large Community Health System.

Danny McNatty, Pharm.D., BCPS, John M. Silverberg, Pharm.D., BCNSP, Brenda S. Stoffer, RN, Nick Sindorf, MT, CLE, Joel D. McAlduff, M.D.; Banner Health, Phoenix, AZ

169. Evaluation of the Immunogenicity and Safety of Recombinant Human Thrombin After Subsequent Surgical Reexposure.

W. Allan Alexander, M.D.,¹ Antonios P. Gasparis, M.D.,² Kaj Johansen, M.D.,³ Jeffrey L. Ballard, M.D.,⁴ Neil K. Singla, M.D.⁵; (1)ZymoGenetics, Inc., Seattle, WA; (2)Stony Brook University Hospital, Stony Brook, NY; (3)Swedish Medical Center, Seattle, WA; (4)Vascular and Interventional Specialists of Orange County, Orange, CA; (5)Lotus Clinical Research, Inc., Pasadena, CA

Neurology

172E. Prospective Evaluation of Labetalol vs. Nicardipine for Blood Pressure Management in Patients with Acute Stroke.

Denise H. Rhoney, Pharm.D.,¹ Xi Liu-DeRyke, Pharm.D.,² Dennis Parker Jr., Pharm.D.,¹ Benjamin Atkinson, M.D.,¹ William Coplin, M.D.,¹ Phillip Levy, M.D.¹; (1)Wayne

State University, Detroit, MI; (2)Orlando Regional Medical Center, Orlando, FL

Psychiatry

201E. Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults with Attention-Deficit/Hyperactivity Disorder in the Simulated Adult Workplace Environment. Timothy Wigal, Ph.D.,¹ Joseph Gao, Ph.D.,² Maria Gasior, M.D.,² John Giblin, M.D.,³ *Steve Valliere, Pharm.D.*,² Matthew Brams, M.D.,⁴; (1)University of California, Irvine Child Development Center, Irvine, CA; (2)Shire Development Inc., Wayne, PA; (3)Clinical Study Centers, LLC, Little Rock, AR; (4)Bayou City Research, Houston, TX

Pulmonary

202E. Omalizumab May Normalize IgE Production Rate in Patients with Moderate-to-Severe Atopic Asthma. Philip Lowe, Ph.D.,¹ Stacey Tannenbaum, Ph.D.,² Aurelie Gautier, M.A.,¹ *Marc Massanari, Pharm.D.*²; (1)Novartis Pharma AG, Basel, Switzerland; (2)Novartis Pharmaceuticals Corporation, East Hanover, NJ

Rheumatology

203E. Gout Subjects with Hyperuricemia and Renal Impairment Treated with Febuxostat or Allopurinol for 6 Months. *Andrew Whelton, M.D.*,¹ Michael A. Becker, M.D.,² Patricia MacDonald, NP,³ Barbara J. Hunt, M.S.,³ Robert L. Jackson, M.D.,³; (1)UCRC Inc. & Johns Hopkins University School of Medicine, Hunt Valley, MD; (2)University of Chicago, Pritzker School of Medicine, Chicago, IL; (3)Takeda Global Research & Development Center, Inc., Deerfield, IL

204. Multiple-Dose Colchicine Administration, as Prescribed for Prophylactic Treatment of Gout, Has No Effect on Single-Dose Theophylline Plasma Concentrations in Healthy Volunteers. *Matthew Davis, M.D., RPh*,¹ Suman Wason, M.D., MBA,¹ Jennifer DiGiacinto, Pharm.D.,²; (1)URL Pharma, Inc., Philadelphia, PA; (2)Salamandra, LLC, Bethesda, MD

Transplant/Immunology

205. Development and Validation of Limited Sampling Strategies for Tacrolimus and Mycophenolate in Steroid-Free Renal Transplant Regimens. Eric Poulin, BScPharm,¹ Erica D. Greanya, BScPharm, Pharm.D., ACPR,¹ Nilufar Partovi, BScPharm, Pharm.D.,² R. Jean Shapiro, M.D., FRCPC,³ Mai Al-Khatib, BScPharm, MScPharm,⁴ *Mary H.H. Ensom, Pharm.D., FASHP, FCCP, FCSHP, FCAHS*⁵; (1)Vancouver General Hospital, Vancouver, BC, Canada; (2)University of British

Columbia and Vancouver General Hospital, Vancouver, BC, Canada; (3)University of British Columbia, Vancouver General Hospital, Vancouver, BC, Canada; (4)University of British Columbia, Vancouver, BC, Canada; (5)University of British Columbia, Children's & Women's Health Centre of British Columbia, Vancouver, BC, Canada

206. Pharmacokinetics of Tacrolimus in Stable Renal Transplant Recipients on a Steroid-Free Regimen. Eric Poulin, BScPharm,¹ Erica D. Greanya, BScPharm, Pharm.D., ACPR,¹ Nilufar Partovi, BScPharm, Pharm.D.,² R. Jean Shapiro, M.D., FRCPC,³ Mai Al-Khatib, BScPharm, MScPharm,⁴ *Mary H.H. Ensom, Pharm.D., FASHP, FCCP, FCSHP, FCAHS*⁵; (1)Vancouver General Hospital, Vancouver, BC, Canada; (2)University of British Columbia and Vancouver General Hospital, Vancouver, BC, Canada; (3)University of British Columbia, Vancouver General Hospital, Vancouver, BC, Canada; (4)University of British Columbia, Vancouver, BC, Canada; (5)University of British Columbia, Children's & Women's Health Centre of British Columbia, Vancouver, BC, Canada

207. Immunosuppressant Adherence Rates in the Mycophenolic Acid Observational Renal Transplant (MORE) Registry. *Marie Chisholm-Burns, Pharm.D., MPH*,¹ Anne Wiland, Pharm.D., BCPS,² Demetra Tsapepas, Pharm.D.,³; (1)The University of Arizona College of Pharmacy, Tucson, AZ; (2)Novartis Pharmaceutical Corporation, East Hanover, NJ; (3)NY-Presbyterian Hospital-Columbia University Medical Center, New York, NY

208. Early Outcome Analysis of the Mycophenolic Acid Observational Renal Transplant (MORE) Registry: Initial Comparisons of Enteric-Coated Mycophenolate Sodium and Mycophenolate Mofetil. *Ali Olyaei, Pharm.D., BCPS*,¹ Anne Wiland, Pharm.D., BCPS,² Kimi Ueda Stevenson, Pharm.D., BCPS³; (1)Oregon State University/Oregon Health and Sciences University, Portland, OR; (2)Novartis Pharmaceutical Corporation, East Hanover, NJ; (3)California Pacific Medical Center, San Francisco, CA

209. Predictors of Recurrent Hepatitis C Treatment Success in Liver Transplantation. *Shirley M. Tsunoda, Pharm.D.*,¹ Mo Cui, Pharm.D.,¹ Judy Hsiao, Pharm.D.,¹ Rachel Sperling, Pharm.D.,¹ Tarek I. Hassanein, M.D.,²; (1)UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA; (2)University of California, San Diego, San Diego, CA

210. Mycophenolate Sodium vs. Mycophenolate Mofetil in Kidney Transplant Recipients Withdrawn from Corticosteroids: An Analysis of the Mycophenolic Acid Observational Renal Transplant Registry (MORE).

Kimi Ueda Stevenson, Pharm.D., BCPS,¹ Anne Wiland, Pharm.D., BCPS,² Ali Olyaei, Pharm.D., BCPS,³ V. Ram Peddi, M.D.¹; (1)California Pacific Medical Center, San Francisco, CA; (2)Novartis Pharmaceutical Corporation, East Hanover, NJ; (3)Oregon State University/Oregon Health and Sciences University, Portland, OR

211. Patient Self-Efficacy and Satisfaction After Medication Education Following Solid-Organ Transplantation.

Seth D. Heldenbrand, Pharm.D.,¹ Lindsey E. Turnbow, Pharm.D.,¹ Nalin Payakachat, Ph.D.²; (1)University of Arkansas for Medical Sciences, Little Rock, AR; (2)University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR

212. Impact of Post-operative Hyperglycemia on Clinical Outcomes in Non-diabetic Renal Transplant Recipients.

Steven Gabardi, Pharm.D.,¹ Michele Campolieto, Pharm.D.²; (1)Pharmacy Department & Renal Division, Brigham and Women's Hospital; Department of Medicine, Harvard Medical School, Boston, MA; (2)Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA

213. Evaluation of Atovaquone versus Sulfamethoxazole-Trimethoprim as *Pneumocystis jiroveci* Pneumonia Prophylaxis Following Renal Transplantation.

Steven Gabardi, Pharm.D.; Pharmacy Department & Renal Division, Brigham and Women's Hospital; Department of Medicine, Harvard Medical School, Boston, MA

214. Evaluation of Early Corticosteroid Cessation Therapy in Standard Criteria Donor versus Expanded Criteria Donor Renal Transplant Recipients.

Steven Gabardi, Pharm.D.; Pharmacy Department & Renal Division, Brigham and Women's Hospital; Department of Medicine, Harvard Medical School, Boston, MA

215. Retrospective Analysis of the Efficacy of Erythropoiesis-Stimulating Agents (ESAs) in the Treatment of Anemia Following Renal Transplantation.

Nicole M. Schmidt, Pharm.D., Teresa Cavanaugh, Pharm.D., Amit Govil, M.D., Gautham Mogilishetty, M.D., Adele Rike Shields, Pharm.D., Nicholas Parrish, M.D.; The Health Alliance, Cincinnati, OH

Women's Health

216E. Genetic and Environmental Risk Factors for Postpartum Depression.

Shareen Y. El-Ibiary, Pharm.D., BCPS,¹ Steven Hamilton, M.D., Ph.D.,² Carolyn Erdman, M.S.,² Patricia Robertson, M.D.,² Rebecca Abel, LCSW,² Patrick R. Finley, Pharm.D.²; (1)Midwestern University, College of

Pharmacy-Glendale, Glendale, CA; (2)University of California at San Francisco, San Francisco, CA

217E. Angiotensin-Converting Enzyme Inhibitor, Angiotensin-Receptor Blocker, and HMG-CoA Reductase Inhibitor Use in Women of Childbearing Potential.

Alison M. Walton, Pharm.D., BCPS, Karie A. Morrical-Kline, Pharm.D., Tracey M. Guildenbecher, M.D.; St. Vincent Joshua Max Simon Primary Care Center, Indianapolis, IN

218. The Impact of Pharmacist Counseling on Patient Knowledge of Emergency Contraception.

Denise Ragland, Pharm.D., Nalin Payakachat, Ph.D., Adam Pate, Pharm.D., Sara Harrod, Pharm.D., Candidate, 2011; University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR

219. Evaluation of Adherence, Persistence, and Switching Patterns Among Women Using Six Commonly Prescribed Hormonal Contraceptives.

Amy W. Law, Pharm.D., M.S., Susan H. Foltz Boklage, M.S., Charles Kreilick, Jennifer Pocoski, Pharm.D., Richard F. Lynen, M.D., MBA, Leo Plouffe Jr., M.D., CM; Bayer HealthCare Pharmaceuticals, Wayne, NJ

220. Obstetrical Practitioner Acceptability of Metformin for the Treatment of Gestational Diabetes Mellitus.

Portia N. Davis, Pharm.D.; Texas Southern University College of Pharmacy & Health Sciences, Houston, TX

CLINICAL PHARMACY FORUM

ADR/Drug Interactions

221. The Effects of Fluconazole Gargle on the Interactions of CNI and Hepatotoxicity in Kidney Transplant Recipients.

Heeyoung Ham, M.S.,¹ Sukhyang Lee, Pharm.D., Ph.D.,¹ Hyenoh La, Ph.D.²; (1)Graduate School of Clinical Pharmacy, Sookmyung Women's University, Seoul, South Korea; (2)Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seoul, South Korea

Allergy/Immunology

222. Standardization of Intravenous Desensitizations Among Hospital Inpatients.

Amy C. Go, Pharm.D.,¹ Lam Nguyen, Pharm.D.,¹ Gerard Barber, RPh, MPH,¹ Christine Steckline, Pharm.D.,¹ Stephen C. Dreskin, M.D., Ph.D.²; (1)University of Colorado Hospital, Aurora, CO; (2)University of Colorado Denver School of Medicine, Aurora, CO

Clinical Research

235. A Public Survey on Receptivity to Pharmacy-Directed Clinical Research Educational Resources.

Jill Chappell, Pharm.D.,¹ Zachary Hallinan, M.S.,² Brian P. Schrock, M.S.,¹ Diane Simmons, B.A.,² Dorothy L. Smith, Pharm.D.³; (1)Eli Lilly and Company, Indianapolis, IN; (2)Center for Information and Study on Clinical Research Participation, Boston, MA; (3)Consumer Health Information Corp., McLean, VA

Community Pharmacy Practice

236. A Searchable Health Data Repository to Enhance Community-Based Pharmacy Practice Research.
Amy M. Franks, Pharm.D.; University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR

Critical Care

237. Retrospective Evaluation of the Incidence of Hypoglycemia and Related Outcomes with Intensive Insulin Therapy in Critically Ill Patients.
Maha Kadafour, Pharm.D., Patricia Parker, Pharm.D., Andrea Bechtold, Ph.D., Nancy Wu, M.S., Tina Palmieri, M.D.; University of California Davis, Sacramento, CA

Drug Information

238. Problem-Oriented Medicines Information Services on a Pharmacist-Operated Centre at a University Hospital.
Ana C. Ribeiro Rama, Ph.D.,¹ Cristina M. Silva, Pharm.D.,² José A. Feio, Pharm.D.³; (1)Pharmacy Department, Coimbra University Hospitals and Center for Pharmaceutical Studies, Faculty Pharmacy, Coimbra University, Coimbra, Portugal; (2)Faculty of Pharmacy, Porto University, Porto, Portugal; (3)Hospitais da Universidade de Coimbra, Coimbra, Portugal

Emergency Medicine

251. Impact of Emergency Pharmacist and Emergency Nursing Pneumonia Protocol.
Darrel W. Hughes, Pharm.D., BCPS,¹ Kimberlea King, BSN, RN,² Denise De La Rosa, BSN, RN, CEN, CCRN²; (1)University Health System/University of Texas Health Science Center San Antonio, San Antonio, TX; (2)University Health System, San Antonio, TX

Family Medicine

252. Effect of Pharmacist Interventions on the Management of Diabetes Mellitus, Hypertension, and Hyperlipidemia in a Family Medicine Clinic.
Erin Lockard, Pharm.D.,¹ James D. Hoehns, Pharm.D.²; (1)Northeast Iowa Family Practice Center, Waterloo, IA; (2)University of Iowa College of Pharmacy/Northeast Iowa Family Practice Center, Waterloo, IA

Gastroenterology

253. Eicosapentaenoic Acid and Docosahexaenoic Acid Synergistically Attenuate Bile Acid-Induced Hepatocellular Apoptosis.

Emma M. Tillman, Pharm.D., Richard A. Helms, Pharm.D., Dennis D. Black, M.D.; University of Tennessee Health Science Center, Memphis, TN

254. Outcomes of a Pharmacist-Driven Protocol for Albumin Use in Patients with Liver Cirrhosis.
Kayta Kobayashi, Pharm.D., BCPS,¹ Alissa Raines, Pharm.D., BCPS,² Joey Wilkinson, Pharm.D.,² Travis B. Dick, Pharm.D., BCPS,² Gordon Harmston, M.D.³; (1)University of Southern Nevada, College of Pharmacy, South Jordan, UT; (2)Intermountain Medical Center, Murray, UT; (3)Mountain West Gastroenterology, Salt Lake City, UT

Health Services Research

255E. Use of an Interactive Online Information Service to Improve Patient Care in the Field of Anticoagulation and Antithrombotic Therapy.

Henry I. Bussey Jr., B.S., Pharm.D.,¹ Marie Walker, BBA²; (1)University of Texas HSC and Genesis Clinical Research, San Antonio, TX; (2)ClotCare, San Antonio, TX

Informatics

260. Implementation of Pharmacy Consult Orders via Computerized Provider Order Entry Utilizing an Electronic Medical Record in an Academic Teaching Hospital.

Kristin S. Alvarez, Pharm.D., Anita P. Rahman, Pharm.D., Carol Chamberlain, Pharm.D., Travis Cooper, Pharm.D., Alissa Lockwood, Pharm.D., Carrie Berge, Pharm.D.; Parkland Hospital, Dallas, TX

Managed Care

261. Pharmacist-Driven Prescription Medication Savings for Employees of a Self-Insured Employer.

Jeanette L. Altavela, Pharm.D., BCPS, Thomas A. Sorrento, RPh, CGP, Cori A. Wyman, Pharm.D., CDE, Michael T. Van Ornum, RPh, RN, BCPS; Greater Rochester Independent Practice Association, Rochester, NY

262. Evaluation of a Dynamic Therapeutic Conversion Initiative from Felodipine to Amlodipine.

Karim Prasla, Pharm.D., M.S.,¹ Yoona A. Kim, Pharm.D.,² Paul J. Godley, Pharm.D.¹; (1)Scott & White Health Plan, Temple, TX; (2)University of Texas at Austin, Austin, TX

Medication Safety

263. Identifying Gaps in Documentation of Anticoagulation Counseling.

Catherine D. Lewis, Pharm.D., CACP, BCPS,¹ Chadana Barnum-Parker, RPh, Pharm.D., Candidate,² Kristen Engel, Pharm.D.,² Jenna Huggins, Pharm.D., BCPS,² Lynn Eschenbacher, Pharm.D., MBA²; (1)Campbell University/WakeMed Health and Hospitals, Raleigh, NC; (2)WakeMed Health and Hospitals, Raleigh, NC

264. A Multi-disciplinary Approach to Inpatient Management of Prostacyclin Therapy for Pulmonary Arterial Hypertension Patients.

Laura A. Duvall, Pharm.D., BCPS; The Ohio State University Medical Center, Columbus, OH

265. Initial Dosing and Monitoring of Argatroban: Impact of Computerized Clinical Decision Support.

Ashley L. Quintili, Pharm.D., BCPS, Bob Lobo, Pharm.D., BCPS, Josh Peterson, M.D., MPH; Vanderbilt University Medical Center, Nashville, TN

266. Compliance to Immunosuppressives in Renal Transplantation – Case of Tacrolimus and Sirolimus.

Clara M. Sequeira, Pharm.D.,¹ Ana C. Ribeiro Rama, Ph.D.,² José A. Feio, Pharm.D.,³ Alfredo Mota, Ph.D.,⁴ Carlos A. Fontes Ribeiro, Ph.D.⁵; (1)Coimbra University Hospital, Coimbra, Portugal; (2)Pharmacy Department, Coimbra University Hospitals and Center for Pharmaceutical Studies, Faculty Pharmacy, Coimbra University, Coimbra, Portugal; (3)Hospitais da Universidade de Coimbra, Coimbra, Portugal; (4)Department of Urology and Renal Transplantation, Coimbra University Hospitals, Coimbra, Portugal; (5)Faculty of Medicine, Coimbra University, Coimbra, Portugal

Nephrology

267. Pharmacist-Performed Educational Intervention in Dialysis Patients with Hyperphosphatemia.

Betty Ha, Pharm.D., Renee Weng, Pharm.D., Madeleine Pahl, M.D., Ashish Kalthia, M.D.; UC-Irvine, Orange, CA

Neurology

268. Clinical Pharmacy Roles on the Brain Attack Team: Focus on Timely Administration of Tissue Plasminogen Activator (tPA).

Frank Diaz, Pharm.D.,¹ Kevin O. Rynn, Pharm.D., FCCP, DABAT,² James S. McKinney, M.D.³; (1)Rutgers University, Piscataway, NJ; (2)Rutgers University Ernest Mario School of Pharmacy, Piscataway, NJ; Robert Wood Johnson University Hospital Emergency Department, New Brunswick, NJ; (3)Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ

Nutrition

269. Comparison of the Incidence of Parenteral Nutrition–Associated Liver Disease in Infants with Congenital Heart Disease and Infants with Necrotizing Enterocolitis.

Emma M. Tillman, Pharm.D., Johanna L. Norman, Pharm.D., Candidate, Richard A. Helms, Pharm.D.; University of Tennessee Health Science Center, Memphis, TN

Psychiatry

275. Bridging the Transition from Hospital to Home: Implementation of a Medication Discharge Program.

Jamie Montgomery, RPh, Jessica Harms, Pharm.D., Edie Whipple, RPh, Kristen Sakely, RPh, Tanya Fabian, Pharm.D., Ph.D., BCPP; Western Psychiatric Institute and Clinic, Pittsburgh, PA

276. Development of a Pharmacist-Managed Medication Therapy Management Service (MTMS) in a Mental Health Clinic.

Kimberly Tallian, Pharm.D., BCPP,¹ Jan D. Hirsch, Ph.D.,² Cathy A. Chang, B.S., Pharm.D., Candidate,² Mindl Messinger, Pharm.D., Candidate,² Todd Gilmer, Ph.D.,³ Grace M. Kuo, Pharm.D., MPH,² Pauline Chan, RPh, MBA, BCPP,⁴ Charles E. Daniels, Ph.D.,² Kelly C. Lee, Pharm.D., BCPP²; (1)University of California, San Diego Medical Center, San Diego, CA; (2)University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA; (3)UCSD Department of Family and Preventive Medicine UCSD School of Medicine, San Diego, CA; (4)Senior Pharmaceutical Consultant, Pharmacy Benefits Division, Department of Health Care Services, Sacramento, CA

277. Evaluation of Metabolic Effects and Monitoring Frequency with Quetiapine.

Marra J. Burr, B.S., Pharm.D., Tami Argo, Pharm.D., Jason Egge, Pharm.D., Shella Johnson, Pharm.D.; Iowa City Veterans Affairs Medical Center, Iowa City, IA

Transplant/Immunology

278. Tolerability of De Novo Maintenance Immunosuppressive Therapy with Sirolimus versus Mycophenolic Acid in Combination with Tacrolimus and Prednisone in Renal Transplant Recipients – 12-Month Results.

Kwaku Marfo, Pharm.D., Julie Chen, Pharm.D., Amy Lu, M.D., Javier Chapochnick, M.D.; Montefiore Medical Center, Bronx, NY

Women's Health

279E. Improving Adherence to Oral Bisphosphonates Through Focused Telephonic Pharmacist Intervention.

Amy Steinkellner, Pharm.D., Laurie Greenberg, M.D., Sandra Eldridge, Pharm.D., Lisa Lenzi, Pharm.D., Shannon Denison, M.A.; Medco Health Solutions, Inc., Tampa, FL

RESIDENTS AND FELLOWS RESEARCH IN PROGRESS

Clinical Administration

286. Evaluating the Clinical and Economic Impact of an Electronic Real-time Patient Surveillance System in a Community Hospital.
Manal Rassam, Pharm.D.; Saint Barnabas Medical Center, Belleville, NJ

Community Pharmacy Practice

287. Re-engineering the Discharge Prescription Delivery Service at Intermountain Medical Center.
Derrick C. Shepherd, Pharm.D.; Intermountain Healthcare, Murray, UT

Critical Care

288. An Evaluation of Scheduled versus Symptom-Driven Alcohol Withdrawal Therapy in the Intensive Care Unit.
Amber L. Elliott, Pharm.D.,¹ Krystal K. Haase, Pharm.D.,¹ Shawna King, Pharm.D.,¹ Harvey M. Richey III, M.S., D.O., MBA, FCCP²; (1)Texas Tech Health Sciences Center School of Pharmacy, Amarillo, TX; (2)Texas Tech Health Sciences Center School of Medicine, Amarillo, TX

Gastroenterology

290. Evaluation of Octreotide Prescribing Patterns at a Tertiary Care Center.
Erin N. Frazee, Pharm.D., Jenna K. Lovely, Pharm.D., John G. O'Meara, Pharm.D.; Mayo Clinic, Rochester, MN

Managed Care

295. Prevalence of Meeting the A1c, Blood Pressure, and Cholesterol (ABC) Goal in Veterans with Diabetes Mellitus at the Iowa City Veterans Affairs (ICVA) Medical Center.
Scott M. Vouri, Pharm.D., Robert Shaw, Pharm.D., MPH, Nancee Waterbury, Pharm.D., Jason Egge, Pharm.D., M.S., BCPS, Bruce Alexander, Pharm.D., BCPP; Iowa City VAMC, Iowa City, IA

Pulmonary

297. Respiratory Outcomes Associated with Inhibition of the Renin-Angiotensin-Aldosterone System Among Patients with Chronic Obstructive Pulmonary Disease.

Cory E. Fominaya, Pharm.D., Jack Brown, M.S., Pharm.D., Fred Doloresco, M.S., Pharm.D., Scott V. Monte, Pharm.D.; SUNY: University at Buffalo, Buffalo, NY

Transplant/Immunology

298. To Load or Not to Load: Comparison of a Mycophenolic Acid Oral Load vs. Standard Dosing.
Jamie Joseph, Pharm.D.,¹ James Thielke, Pharm.D.,² Patricia West-Thielke, Pharm.D.³; (1)University of Illinois at Chicago, Morton Grove, IL; (2)University of Illinois Medical Center at Chicago (UIMCC), Chicago, IL; (3)University of Illinois at Chicago, Chicago, IL

299. Conversion of Prograf® to Generic Tacrolimus (Sandoz) in Stable Renal Transplant Recipients.
Barrett R. Crowther, Pharm.D.,¹ Heather Dobie, Pharm.D.,¹ Rebecca Brady, Pharm.D., BCPS,¹ Reed C. Hall, Pharm.D., BCPS,¹ Cody L. Allison, Pharm.D., BCPS,¹ Kay Green, RPh, BCPS,² Pamela R. Maxwell, Pharm.D., BCPS¹; (1)University Transplant Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX; (2)University Health System, San Antonio, TX

LATE BREAKERS

Community Pharmacy Practice

349. A Survey of NC Pharmacists Regarding Mandatory Medication Counseling.
Roy A. Pleasants, Pharm.D.,¹ Carolyn Robbins, BSPharm, Pharm.D.,² Brenden Ohara, RPh,³ Dan Garrett, RPh, M.S.,⁴ Charli Davis, Pharm.D., Student,⁵ Robert Cisneros, Ph.D.⁵; (1)Campbell University, Cary, NC; (2)Lincoln Community Health Center Pharmacy, Durham, NC; (3)Physician's Pharmacy, Cary, NC; (4)American Healthcare, Rocklin, CA; (5)Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC

Critical Care

350. Effect of ACE Inhibitors on Renal Function in a Surgical Critical Care Population.
April D. Miller, Pharm.D., BCPS, P. Brandon Bookstaver, Pharm.D., BCPS (AQ-ID), AAHIVE, Katie Barber, Pharm.D.; South Carolina College of Pharmacy-USC Campus, Columbia, SC

Nephrology

353. Pilot Evaluation of Renal Function in Hispanic Americans with Diabetes.
Thomas C. Dowling, Pharm.D., Ph.D.,¹ Magaly Rodriguez de Bittner, Pharm.D.,¹ Zhanita Perez, Pharm.D.,² Andrew Briglia, M.D.,³ Ligia Peralta, M.D.⁴; (1)Department of

Pharmacy and Therapeutics, University of Maryland, Baltimore, MD; (2)University of Maryland, Baltimore, MD; (3)Annapolis Nephrology Associates, Annapolis, MD; (4)Department of Medicine, University of Maryland, Baltimore, MD

Psychiatry

362E. Prescribing Prevalence of Low-Dose Quetiapine in a Large Academic Medical Center.

Ashley L. Mains, Pharm.D., Karen E. Moeller, Pharm.D., BCPP, Allison R. King, Pharm.D.; University of Kansas Hospital, Kansas City, KS

363. Switching from Olanzapine to Another Antipsychotic: A Naturalistic Study Assessing Success, Safety, and Cost of Conversion.

Ashley M. LaFlame, Pharm.D.,¹ Bethany Dipaula, Pharm.D.,² Jason Noel, Pharm.D.²; (1)Spring Grove Hospital Center, Catonsville, MD; (2)University of Maryland School of Pharmacy, Baltimore, MD

Pulmonary

364E. Brand or Generic? Evaluation of an Epoprostenol Formulary Change.

Laura A. Duvall, Pharm.D., BCPS, Namita Sood, M.D., FCCP; The Ohio State University Medical Center, Columbus, OH

Women's Health

365. Emergency Contraception Skills Workshop for First-Year Pharmacy Students.

Melissa Natavio, M.D., MPH, Kimberly A. Moore, Research Assistant, Penina Segall-Gutierrez, M.D., MSc, Hannah Moon, M.D., Kathleen H. Besinque, Pharm.D., Nicole M. Bender, M.D., Neisha R. Opper, MPH, Deshawn Taylor, M.D., Kathleen A. Johnson, Pharm.D., Ph.D., MPH; USC, Los Angeles, CA